These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 19529771)

  • 1. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose.
    Aagaard C; Hoang TT; Izzo A; Billeskov R; Troudt J; Arnett K; Keyser A; Elvang T; Andersen P; Dietrich J
    PLoS One; 2009 Jun; 4(6):e5930. PubMed ID: 19529771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
    Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
    Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H1:IC31 vaccination is safe and induces long-lived TNF-α
    Mearns H; Geldenhuys HD; Kagina BM; Musvosvi M; Little F; Ratangee F; Mahomed H; Hanekom WA; Hoff ST; Ruhwald M; Kromann I; Bang P; Hatherill M; Andersen P; Scriba TJ;
    Vaccine; 2017 Jan; 35(1):132-141. PubMed ID: 27866772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
    Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
    Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
    Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
    Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Jia Q; Masleša-Galić S; Nava S; Horwitz MA
    mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.
    Agger EM; Rosenkrands I; Olsen AW; Hatch G; Williams A; Kritsch C; Lingnau K; von Gabain A; Andersen CS; Korsholm KS; Andersen P
    Vaccine; 2006 Jun; 24(26):5452-60. PubMed ID: 16675077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
    Elvang T; Christensen JP; Billeskov R; Thi Kim Thanh Hoang T; Holst P; Thomsen AR; Andersen P; Dietrich J
    PLoS One; 2009; 4(4):e5139. PubMed ID: 19357780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological memory transferred with CD4 T cells specific for tuberculosis antigens Ag85B-TB10.4: persisting antigen enhances protection.
    Duffy D; Dawoodji A; Agger EM; Andersen P; Westermann J; Bell EB
    PLoS One; 2009 Dec; 4(12):e8272. PubMed ID: 20011592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy.
    Dietrich J; Aagaard C; Leah R; Olsen AW; Stryhn A; Doherty TM; Andersen P
    J Immunol; 2005 May; 174(10):6332-9. PubMed ID: 15879133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model.
    Billeskov R; Christensen JP; Aagaard C; Andersen P; Dietrich J
    PLoS One; 2013; 8(8):e72185. PubMed ID: 23977248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
    van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
    Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
    Hervas-Stubbs S; Majlessi L; Simsova M; Morova J; Rojas MJ; Nouzé C; Brodin P; Sebo P; Leclerc C
    Infect Immun; 2006 Jun; 74(6):3396-407. PubMed ID: 16714570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
    Suliman S; Luabeya AKK; Geldenhuys H; Tameris M; Hoff ST; Shi Z; Tait D; Kromann I; Ruhwald M; Rutkowski KT; Shepherd B; Hokey D; Ginsberg AM; Hanekom WA; Andersen P; Scriba TJ; Hatherill M;
    Am J Respir Crit Care Med; 2019 Jan; 199(2):220-231. PubMed ID: 30092143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alarmin IL-33 elicits potent TB-specific cell-mediated responses.
    Villarreal DO; Siefert RJ; Weiner DB
    Hum Vaccin Immunother; 2015; 11(8):1954-60. PubMed ID: 26091147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.
    Bennekov T; Dietrich J; Rosenkrands I; Stryhn A; Doherty TM; Andersen P
    Eur J Immunol; 2006 Dec; 36(12):3346-55. PubMed ID: 17109467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of multiple TB antigens TB10.4 and TB10.4-Ag85B as subunit vaccine candidates against Mycobacterium tuberculosis.
    Shi S; Yu L; Sun D; Liu J; Hickey AJ
    Pharm Res; 2010 Feb; 27(2):224-34. PubMed ID: 19862606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
    Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
    PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.